Infectious Disease Molecular Diagnostics Market Worth $40.8 Billion By 2028

The global infectious disease molecular diagnostics market size is estimated to arrive at USD 40.8 billion by 2028. It is projected to develop by 3.0% CAGR from 2020 to 2028.

The market for infectious disease molecular diagnostics is pushed by the induction of technically sophisticated products in addition to an enhancement in demand for the molecular diagnostics in PoC location.

Cost-effectiveness, fast technical progression together with portability and precise outcomes are the factors, expected to perform like a fundamental drivers of the market.

The technologies like In Situ Hybridization (ISH), Isothermal Nucleic Acid Amplification Technology (INAAT) and mass spectroscopy are complex and as contrast to other established diagnostic tests, contain a short false-positive percentage. Advantages like the ease of use as well as cost-effectiveness of this technology plus the precision presented are likely to boost the implementation of this infectious disease molecular diagnostics technology.

The application of the molecular diagnostics in research establishments is rising. The utilization of the procedures like southern blotting, PCR, and western blotting is happening to be universal. Besides, the global increase of SARS-CoV-2 infectivity has initiated the growth in financial support for research activities by the diagnostic companies in addition to governments, to investigate for novel molecular diagnostics.

Molecular diagnostics provide precise as well as successful outcomes. In addition, these tests facilitate the premature discovery of the illness, retaining a low down risk of the replacement.

 To request a sample copy or view summary of this report, "please" click the link below:

 https://www.millioninsights.com/industry-reports/global-infectious-disease-molecular-diagnostics-market

Further key findings from the report suggest:

• In Asia Pacific, the elevated enlargement speed of the infectious disease molecular diagnostics market can be credited to better admittance to healthcare in the budding nations

• Due to lesser complications and extraordinary sensitivity the In Situ Hybridization (ISH) division of the market, is projected to observe the highest development speed

• The rising elderly populace in Asian nations, like China and Japan, along with the greater available openings is likely to power the market growth within the region, throughout the forecast period

• As a result of augmented acceptance, the reagent sector is anticipated to reveal the highest enlargement speed, during the forecast period

Million Insights segmented the global infectious disease molecular diagnostics market based on End Use, Application, Technology, Product, and Region.

Infectious Disease Molecular Diagnostics Product Outlook (Revenue, USD Million, 2017 - 2028)
    • Instruments
    • Reagents
    • Services

Infectious Disease Molecular Diagnostics End-use Outlook (Revenue, USD Million, 2017 - 2028)
    • Hospitals
    • Clinics
    • Diagnostics Laboratories
    • Research Institutes

Infectious Disease Molecular Diagnostics Technology Outlook (Revenue, USD Million, 2017 - 2028)
    • Polymerase Chain Reaction (PCR)
        • PCR, by Type
            • Multiplex PCR
            • Other PCR
        • PCR, by Product
            • Instruments
            • Reagents
            • Services
    • In Situ Hybridization
        • Instruments
        • Reagents
        • Services
    • Isothermal Nucleic Acid Amplification Technology (INAAT)
        • Instruments
        • Reagents
        • Services
    • Chips and Microarrays
        • Instruments
        • Reagents
        • Services
    • Mass Spectrometry
        • Instruments
        • Reagents
        • Services
    • Sequencing
        • Instruments
        • Reagents
        • Services
    • Transcription Mediated Amplification
        • Instruments
        • Reagents
        • Services
    • Others
        • Instruments
        • Reagents
        • Services

Infectious Disease Molecular Diagnostics Application Outlook (Revenue, USD Million, 2017 - 2028)
    • Respiratory Diseases
    • Tuberculosis
    • Meningitis
    • Gastrointestinal Tract Infections
    • HPV
    • Sexually Transmitted Infections
    • Sepsis
    • Drug Resistance Diseases
    • Other Infectious Diseases

Respiratory Diseases Outlook (Revenue, USD Million, 2017 - 2028)
    • Respiratory Diseases, By Product (Revenue, USD Million, 2017 - 2028)
        • Instruments
        • Reagents
        • Services
    • Respiratory Diseases, By End Use (Revenue, USD Million, 2017 - 2028)
        • Hospitals
        • Clinics
        • Diagnostics Laboratories
        • Research Institutes
    • Respiratory Diseases, By Technology, (Number of Tests Performed from 2017 - 2028 in Million) (Revenue, USD Million, 2017 - 2028)
        • Polymerase chain reaction (PCR)
        • In Situ Hybridization
        • Isothermal Nucleic Acid Amplification Technology (INAAT)
        • Chips and Microarrays
        • Mass Spectrometry
        • Sequencing
        • Transcription Mediated Amplification
        • Others

Tuberculosis Outlook (Revenue, USD Million, 2017 - 2028)
    • Tuberculosis, By Product (Revenue, USD Million, 2017 - 2028)
        • Instruments
        • Reagents
        • Services
    • Tuberculosis, By End Use (Revenue, USD Million, 2017 - 2028)
        • Hospitals
        • Clinics
        • Diagnostics Laboratories
        • Research Institutes
    • Tuberculosis, By Technology, (Number of Tests Performed from 2017 - 2028 in Million) (Revenue, USD Million, 2017 - 2028)
        • Polymerase chain reaction (PCR)
        • In Situ Hybridization
        • Isothermal Nucleic Acid Amplification Technology (INAAT)
        • Chips and Microarrays
        • Mass Spectrometry
        • Sequencing
        • Transcription Mediated Amplification
        • Others

Meningitis Outlook (Revenue, USD Million, 2017 - 2028)
    • Meningitis, By Product (Revenue, USD Million, 2017 - 2028)
        • Instruments
        • Reagents
        • Services
    • Meningitis, By End Use (Revenue, USD Million, 2017 - 2028)
        • Hospitals
        • Clinics
        • Diagnostics Laboratories
        • Research Institutes
    • Meningitis, By Technology, (Number of Tests Performed from 2017 - 2028 in Million) (Revenue, USD Million, 2017 - 2028)
        • Polymerase chain reaction (PCR)
        • In Situ Hybridization
        • Isothermal Nucleic Acid Amplification Technology (INAAT)
        • Chips and Microarrays
        • Mass Spectrometry
        • Sequencing
        • Transcription Mediated Amplification
        • Others

Gastrointestinal Tract Infections Outlook (Revenue, USD Million, 2017 - 2028)
    • Gastrointestinal Tract Infections, By Product (Revenue, USD Million, 2017 - 2028)
        • Instruments
        • Reagents
        • Services
    • Gastrointestinal Tract Infections, By End Use (Revenue, USD Million, 2017 - 2028)
        • Hospitals
        • Clinics
        • Diagnostics Laboratories
        • Research Institutes
    • Gastrointestinal Tract Infections, By Technology, (Number of Tests Performed from 2017 - 2028 in Million) (Revenue, USD Million, 2017 - 2028)
        • Polymerase chain reaction (PCR)
        • In Situ Hybridization
        • Isothermal Nucleic Acid Amplification Technology (INAAT)
        • Chips and Microarrays
        • Mass Spectrometry
        • Sequencing
        • Transcription Mediated Amplification
        • Others

HPV Outlook (Revenue, USD Million, 2017 - 2028)
    • HPV, By Product (Revenue, USD Million, 2017 - 2028)
        • Instruments
        • Reagents
        • Services
    • HPV, By End Use (Revenue, USD Million, 2017 - 2028)
        • Hospitals
        • Clinics
        • Diagnostics Laboratories
        • Research Institutes
    • HPV, By Technology, (Number of Tests Performed from 2017 - 2028 in Million) (Revenue, USD Million, 2017 - 2028)
        • Polymerase chain reaction (PCR)
        • In Situ Hybridization
        • Isothermal Nucleic Acid Amplification Technology (INAAT)
        • Chips and Microarrays
        • Mass Spectrometry
        • Sequencing
        • Transcription Mediated Amplification
        • Others

Sexually Transmitted Infections Outlook (Revenue, USD Million, 2017 - 2028)
    • Sexually Transmitted Infections, By Product (Revenue, USD Million, 2017 - 2028)
        • Instruments
        • Reagents
        • Services
    • Sexually Transmitted Infections, By End Use (Revenue, USD Million, 2017 - 2028)
        • Hospitals
        • Clinics
        • Diagnostics Laboratories
        • Research Institutes
    • Sexually Transmitted Infections, By Technology, (Number of Tests Performed from 2017 - 2028 in Million) (Revenue, USD Million, 2017 - 2028)
        • Polymerase chain reaction (PCR)
        • In Situ Hybridization
        • Isothermal Nucleic Acid Amplification Technology (INAAT)
        • Chips and Microarrays
        • Mass Spectrometry
        • Sequencing
        • Transcription Mediated Amplification
        • Others

Sepsis Outlook (Revenue, USD Million, 2017 - 2028)
    • Sepsis, By Product (Revenue, USD Million, 2017 - 2028)
        • Instruments
        • Reagents
        • Services
    • Sepsis, By End Use (Revenue, USD Million, 2017 - 2028)
        • Hospitals
        • Clinics
        • Diagnostics Laboratories
        • Research Institutes
    • Sepsis, By Technology, (Number of Tests Performed from 2017 - 2028 in Million) (Revenue, USD Million, 2017 - 2028)
        • Polymerase chain reaction (PCR)
        • In Situ Hybridization
        • Isothermal Nucleic Acid Amplification Technology (INAAT)
        • Chips and Microarrays
        • Mass Spectrometry
        • Sequencing
        • Transcription Mediated Amplification
        • Others

Drug Resistance Disease Outlook (Revenue, USD Million, 2017 - 2028)
    • Drug Resistance Disease, By Product (Revenue, USD Million, 2017 - 2028)
        • Instruments
        • Reagents
        • Services
    • Drug Resistance Disease, By End Use (Revenue, USD Million, 2017 - 2028)
        • Hospitals
        • Clinics
        • Diagnostics Laboratories
        • Research Institutes
    • Drug Resistance Disease, By Technology, (Number of Tests Performed from 2017 - 2028 in Million) (Revenue, USD Million, 2017 - 2028)
        • Polymerase chain reaction (PCR)
        • In Situ Hybridization
        • Isothermal Nucleic Acid Amplification Technology (INAAT)
        • Chips and Microarrays
        • Mass Spectrometry
        • Sequencing
        • Transcription Mediated Amplification
        • Others

Infectious Disease Molecular Diagnostics Regional Outlook (Revenue, USD Million, 2017 - 2028)
    • North America
        • U.S.
        • Canada
    • Europe
        • U.K.
        • Germany
        • France
        • Italy
        • Spain
    • Asia Pacific
        • Japan
        • China
        • India
        • South Korea
        • Australia
    • Latin America
        • Brazil
        • Mexico
        • Argentina
    • Middle East & Africa
        • South Africa
        • Saudi Arabia
        • UAE

Companies

Various companies for infectious disease molecular diagnostics market are:

• Siemens Healthineers AG
• Grifols S.A.
• Hologic, Inc. (Gen-Probe)
• Agilent Technologies, Inc.
• F. Hoffmann-La Roche Ltd
• Danaher Corporation
• Sysmex Corporation
• Qiagen
• Illumina, Inc.
• Becton, Dickinson and Company
• Bio-Rad Laboratories, Inc.
• bioMérieux SA
• Abbott